Specify a stock or a cryptocurrency in the search bar to get a summary
New Horizon Health Ltd
6606New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2015 and is headquartered in Hangzhou, China. Address: T1 Building, Hangzhou, China, 310052
Analytics
WallStreet Target Price
359.54 HKDP/E ratio
58.9167Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 6606
Dividend Analytics 6606
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 6606
Stock Valuation 6606
Financials 6606
Results | 2019 | Dynamics |